Yukon Immunization Program Manual

Section 8 - Biological Products

Monoclonal Antibody (Palivizumab)

SECTION 8 – BIOLOGICAL PRODUCTS

Contents

2020 December	
Palivizumab (SYNAGIS®) **Supplier: Astra Zeneca**	
INDICATIONS	**DOSES AND SERIES**
Recommended and provided free to: • Premature infants that meet the criteria of the RSV program. Only to be administered to those who have received approval to be enrolled in the program ❶	15mg/kg body weight, by IM injection ❷ Refer to Yukon Immunization Program Manual, Section 5, for detailed information on the RSV prevention program process
ADMINISTRATION ❷	1) Upon arrival to the health facility, weigh the infant 2) Calculate appropriate dose to be administered based on step 1 3) Administer appropriate dose as per product monograph 4) Enter SYNAGIS® in Panorama 5) Observe client with same procedure as any immunization (15 Minutes) 6) Set date for next injection 7) Advise Immunization Program Manager by phone or email that Synagis® was administered. Include following information: Panorama client ID, weight, dose given, and date of next appointment.
REINFORCEMENT ❸	2nd dose: to be administered 21 days later (can be 18-24 days) Subsequent doses: to be administered 28-30 days later
STORAGE AND HANDLING	Should be kept in a monitored fridge at 2° to 8° Celsius. Do not freeze. Do not dilute or shake vial. Should be administered immediately after drawing up dose.
PRECAUTIONS	• Should be given with caution to patients with thrombocytopenia or any coagulation disorder, and those receiving anticoagulant therapy. • A moderate to severe infection or febrile illness may delay administration, unless stated by a physician. • Synagis® does not interfere with any other immunizations.
CONTRAINDICATIONS	Contraindicated in patients with known hypersensitivity to Palivizumab or other humanized monoclonal antibodies.
PRODUCT COMPONENTS	**Medicinal ingredients:** Palivizumab (humanized monoclonal antibody- 95% human antibody, 5% murine antibody) **Non-medicinal ingredients:** chloride, glycine, histidine
ADVERSE EVENTS	**Local:** pain, redness, swelling. **Systemic:** otitis media, upper respiratory tract infection, rhinitis, rash, fever.

2020 December

Palivizumab (SYNAGIS®)

Supplier: Astra Zeneca

❶ A physician in the Yukon must complete the Yukon RSV Protection Program application form each year. Each health centre is responsible for advising their community physician that Synagis® has been approved for their client. See Yukon Synagis® Acquisition Process in Section 5 pg. 43.

❷ Will come in single-use vials to be drawn up; dose calculated based on infant weight. Round off dose to nearest 5mg. See Section 5 for full details on RSV Prevention Program.

❸ To be administered during RSV season only (typically Nov to Apr). The end of the RSV season will be conveyed by the Immunization Program Manager.